New Experimental Medication Effectively Burns Fat and Controls Blood Sugar Without Muscle Loss
A new oral drug shows potential to effectively burn fat and regulate blood sugar levels while preserving muscle mass, offering hope for better management of type 2 diabetes and obesity without common side effects.
A groundbreaking drug under investigation shows promising results in managing weight and blood sugar levels without the common side effects associated with current diabetes treatments. Recent research published in the journal Cell highlights how this novel medication, developed by researchers from Karolinska Institutet and Stockholm University, could revolutionize treatment strategies for individuals with type 2 diabetes and obesity.
This drug, administered orally in tablet form, operates via a mechanism distinct from the widely used GLP-1 receptor agonists like Ozempic, which function by influencing hunger signals but often lead to appetite suppression, gastrointestinal issues, and muscle mass reduction. Instead, the new compound activates metabolic processes directly within skeletal muscle tissue, resulting in enhanced fat burning and improved blood sugar regulation while preserving muscle mass.
Initial Phase I clinical trials involving 48 healthy volunteers and 25 patients with type 2 diabetes suggest that the medication is well tolerated and effective. This development paves the way for larger Phase II studies, which are planned by Atrogi AB to confirm these effects in a broader patient population.
The research team, including Professor Tore Bengtsson and Assistant Professor Shane C. Wright, explain that the drug is based on a specially designed molecule — a type of β2 agonist — which can stimulate muscle tissue without overstimulating the heart, a common concern with traditional β2 agonists. This promising approach offers the potential for healthy weight loss and improved metabolic health without the adverse side effects typical of current treatments.
Furthermore, because of its different mode of action, the drug could be used in combination therapy with existing GLP-1-based drugs, providing a versatile treatment option. The collaborative research involved institutions from Sweden, Denmark, and Australia, illustrating a significant international effort.
This innovative treatment could marks a substantial step forward in tackling obesity and type 2 diabetes, conditions closely linked to metabolic health, and could improve quality of life for millions worldwide.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Development of Biopsychosocial Criteria for Patients with Deafblindness
A new international initiative has established standardized biopsychosocial criteria for diagnosing and supporting individuals with deafblindness, enhancing global understanding and tailored services.
Nicotine Pouch Use in Adolescents Associated with Reduced Vaping Persistence
Research shows that nicotine pouch use among teens may lower the likelihood of continued vaping, offering insights into youth tobacco behavior and potential harm reduction strategies.
The Closure of a Historic Clinic Marks a Shift in Access to Late-Stage Abortions in the U.S.
The recent closure of a Colorado-based clinic that provided late-term abortions highlights the decreasing access to vital reproductive healthcare services for women with complex medical needs in the U.S.